Mex3a stemness signature as a predictive biomarker of clinical and pathological response to total neoadjuvant therapy in locally advanced rectal cancer
Más información
Fecha de publicación: | 2034 |
Objetivos: | To study the role of E2F3/ MEX3A in chemoradiotherapy resistance and in the prediction of neoadjuvant treatment response in patients with locally advanced rectal cancer |
Instrumento: | Fondecyt Regular |
Año de Inicio/Término: | 2034-2028 |
Financiamiento/Sponsor: | CONICYT |
Rol del Usuario: | COINVESTIGADOR(A) |
DOI: |
1241269 |